date,title,source
Oct-23-18,Newly Granted European Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics' Lead Drug Candidate VB-111 until October 2033,GlobeNewswire
Nov-13-18,VBL Therapeutics to Report Third Quarter 2018 Financial Results on November 20,GlobeNewswire
Nov-16-18,VBL Therapeutics Presents Results from Phase 3 GLOBE Study in Patients with Recurrent Glioblastoma at the 2018 Society for Neuro-Oncology Annual Meeting,GlobeNewswire
Nov-20-18,"Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates",Zacks
Nov-20-18,Vascular Biogenics: 3Q Earnings Snapshot,Associated Press
Nov-20-18,VBL Therapeutics Announces Third Quarter 2018 Financial Results,GlobeNewswire
Nov-21-18,Edited Transcript of VBLT earnings conference call or presentation 20-Nov-18 1:30pm GMT,Thomson Reuters StreetEvents
Nov-21-18,VBL Therapeutics to Present at the Piper Jaffray 30th Annual Healthcare Conference on November 28,GlobeNewswire
Dec-20-18,Read This Before Selling Vascular Biogenics Ltd. (NASDAQ:VBLT) Shares,Simply Wall St.
Feb-19-19,VBL Therapeutics to Present Data on its Novel VB-600 Platform at Keystone Conference on February 26,GlobeNewswire
Feb-20-19,VBL Therapeutics Awarded $2.9 Million Non-Dilutive Grant by the Israel Innovation Authority,GlobeNewswire
Feb-26-19,VBL Presents New Data on the Potential of its Novel VB-600 Platform for Nonalcoholic Steatohepatitis (NASH) and Rheumatoid Arthritis (RA),GlobeNewswire
Mar-11-19,VBL Therapeutics to Present at the Society of Gynecologic Oncology (SGO) 50th Annual Meeting on Women's Cancer on March 18,GlobeNewswire
Mar-14-19,Earnings Preview: Vascular Biogenics (VBLT) Q4 Earnings Expected to Decline,Zacks
Mar-14-19,VBL Therapeutics to Report Fiscal Year 2018 Financial Results on March 28,GlobeNewswire
Mar-19-19,VBL Presents New Data on Potential of VB-111 to Stimulate the Immune System and Drive Immune Cells to Infiltrate Tumor Microenvironment,GlobeNewswire
Mar-21-19,Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for,Zacks
Mar-25-19,VBL Therapeutics to Present at Upcoming Conferences in April,GlobeNewswire
Mar-28-19,"Vascular Biogenics (VBLT) Reports Q4 Loss, Misses Revenue Estimates",Zacks
Mar-28-19,"The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO",Benzinga
Mar-28-19,"VBL Therapeutics Announces Year Ended December 31, 2018 Financial Results and Provides Corporate Update",GlobeNewswire
Mar-29-19,Edited Transcript of VBLT earnings conference call or presentation 28-Mar-19 12:30pm GMT,Thomson Reuters StreetEvents
Apr-04-19,Those Who Purchased Vascular Biogenics (NASDAQ:VBLT) Shares Three Years Ago Have A 54% Loss To Show For It,Simply Wall St.
May-06-19,VBL Therapeutics to Report First Quarter 2019 Financial Results on May 15,GlobeNewswire
